MFMarcos da Silva Freire

Marcos da Silva Freire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcos da Silva Freire has a total of 141 co-authors. Here are the top co-authors by number of shared publications:

  • Akira Homma

    Fundação Oswaldo Cruz, Brazil

    3 shared publications
  • Elena Cristina Caride

    Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos /Bio-Manguinhos, Avenida Brasil 4365, 21040-900 Rio de Janeiro, RJ, Brazil

    3 shared publications
  • Ricardo Galler

    Fundação Oswaldo Cruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Avenida Brasil 4365, Manguinhos, Rio de Janeiro 21045-900, Brazil

    3 shared publications
  • Sheila Maria Barbosa de Lima

    Laboratório de Tecnologia Virológica (LATEV) (Bio-Manguinhos), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro 21040-360, Brazil

    3 shared publications
  • Alcides Pissinatti

    Centro de Primatologia do Rio de Janeiro - CPRJ, Instituto Estadual do Ambiente, Guapimirim, RJ, Brazil; Centro Universitário Serra dos Orgãos, Unifeso, Teresópolis, RJ, Brazil

    2 shared publications
  • Ana Carolina dos Reis Albuquerque Cajaraville

    Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos /Bio-Manguinhos, Avenida Brasil 4365, 21040-900 Rio de Janeiro, RJ, Brazil

    2 shared publications

Latest Publications

  • Open Access

    Safety and Immunogenicity of the Attenuated Yellow Fever Vaccine in Several Neotropical Primate Species

    by Nayara Ferreira de Paula, André Duarte Vieira, Daniel Oliveira dos Santos, Lucas dos Reis de Souza, Carlyle Mendes Coelho, Herlandes Penha Tinoco, Paula Cristina Senra Lima, Rafael Otávio Cançado Motta, Valéria Do Socorro Pereira, Marcelo Pires Nogueira de Carvalho, et al.

    Background/Objective: Yellow fever (YF) is an acute infectious disease caused by the yellow fever virus which is transmitted by mosquitoes. Neotropical primates are susceptible to infection, which is often presented as epizootic outbreaks. The aim was to evaluate and characterize the immune response against YF in different species of neotropical primates from the Belo Horizonte Zoo. Methods: Vaccine 17DD was administered to 24 neotropical primates, with a single subcutaneous dose. Clinical exams, RNAemia, and detection of IgG and neutralizing antibodies against YFV were performed. In addition, an ethogram was performed to assess clinical changes and animal welfare. Results: At 4 days post-vaccination, RNAemia was detected in nine animals. There was seroconversion and persistence of immune response in Alouatta guariba clamitans, Sapajus xanthosternos, Saguinus imperator and Aotus infulatus. However, the vaccine was not immunogenic for Lagothrix cana. In Pithecia irrorata seroconversion did not persist long term, while the Ateles sp. had a transient immune response. No significant clinical manifestations were observed in any of the vaccinated animals. Conclusions: This study demonstrated a safe, immunogenic and persistent immune response induced by the attenuated 17DD vaccine strain in A. guariba clamitans, S. xanthosternos, S. imperator, and A. infulatus.


  • Safety and immunogenicity of different 17DD yellow fever vaccines in golden-headed tamarins (Leontopithecus chrysomelas): Inhibition of viremia and RNAemia after homologous live-attenuated vaccination

    by André Tavares Silva-Fernandes, Silvia Bahadian Moreira, Luciane Pinto Gaspar, Ana Carolina dos Reis Albuquerque Cajaraville, Marisol Simões, Renata Carvalho Pereira, Mariana Pierre de Barros Gomes, Vanessa de Oliveira Santos, Renata Tourinho Santos, Andrea Marques Vieira da Silva, et al.


  • Open Access

    Reply to the Letter to the Editors by Beirão

    by Akira Homma, Marcos da Silva Freire, Cristina Possas

    In his interesting letter to the Editors on our article on vaccines for neglected and emerging diseases 1 1. Homma A, Freire MS, Possas C. Vaccines for neglected and emerging diseases in Brazil by 2030: the "valley of death" and opportunities for RD&I in Vaccinology 4.0. Cad Saúde Pública 2020; 36 Suppl 2:e00128819. , Prof. Beirão 2 2. Beirão BCB. Brazil must complete the cycle in vaccine development. Cad Saúde Pública 2024; 40:e00043024. makes incisive comments and a very positive evaluation of our publication. He also gives important considerations on the main challenges remaining for Brazil to be able to come close to overcoming the “valley of death” in vaccine development by 2030. In summary, he concludes that the COVID-19 pandemic has had “the positive impact of pushing Brazilian R&D towards the goals”, but alerts that “now is the time to keep up the momentum to be able to come close of reaching the goals set in the article” 2 2. Beirão BCB. Brazil must complete the cycle in vaccine development. Cad Saúde Pública 2024; 40:e00043024. (p. 2).

  • Open Access

    Evaluation of Two Adjuvant Formulations for an Inactivated Yellow Fever 17DD Vaccine Candidate in Mice

    by Ana Carolina dos Reis Albuquerque Cajaraville, Mariana Pierre de Barros Gomes, Tamiris Azamor, Renata Carvalho Pereira, Patrícia Cristina da Costa Neves, Paula Mello De Luca, Sheila Maria Barbosa de Lima, Luciane Pinto Gaspar, Elena Caride, Marcos da Silva Freire, et al.

    The attenuated yellow fever (YF) vaccine is one of the most successful vaccines ever developed. After a single dose administration YF vaccine can induce balanced Th1/Th2 immune responses and long-lasting neutralizing antibodies. These attributes endorsed it as a model of how to properly stimulate the innate response to target protective immune responses. Despite their longstanding success, attenuated YF vaccines can cause rare fatal adverse events and are contraindicated for persons with immunosuppression, egg allergy and age < 6 months and >60 years. These drawbacks have encouraged the development of a non-live vaccine. The aim of the present study is to characterize and compare the immunological profile of two adjuvant formulations of an inactivated YF 17DD vaccine candidate. Inactivated YF vaccine formulations based on alum (Al(OH)3) or squalene (AddaVax®) were investigated by immunization of C57BL/6 mice in 3-dose or 2-dose schedules, respectively, and compared with a single dose of attenuated YF virus 17DD. Sera were analyzed by ELISA and Plaque Reduction Neutralization Test (PRNT) for detection of total IgG and neutralizing antibodies against YF virus. In addition, splenocytes were collected to evaluate cellular responses by ELISpot. Both inactivated formulations were able to induce high titers of IgG against YF, although neutralizing antibodies levels were borderline on pre-challenge samples. Analysis of IgG subtypes revealed a predominance of IgG2a associated with improved neutralizing capacity in animals immunized with the attenuated YF vaccine, and a predominance of IgG1 in groups immunized with experimental non-live formulations (alum and AddaVax®). After intracerebral (IC) challenge, attenuated and inactivated vaccine formulations showed an increase in neutralizing antibodies. The AddaVax®-based inactivated vaccine and the attenuated vaccine achieved 100% protection, and alum-based equivalent formulation achieved 70% protection.


  • Open Access

    Neotropical Sylvatic Mosquitoes and Aedes aegypti Are Not Competent to Transmit 17DD Attenuated Yellow Fever Virus from Vaccinated Viremic New World Non-Human Primates

    by Rafaella Moraes de Miranda, Rosilainy Surubi Fernandes, André Tavares da Silva-Fernandes, Anielly Ferreira-De-Brito, Silvia Bahadian Moreira, Renata Carvalho Pereira, Ygara da Silva Mendes, Sheila Maria Barbosa de Lima, Alcides Pissinatti, Marcos da Silva Freire, et al.

    Beside humans, thousands of non-human primates (NHPs) died during the recent outbreak caused by the yellow fever virus (YFV) in Brazil. Vaccination of NHPs against YFV with the YF 17DD attenuated virus has emerged as a public health strategy, as it would reduce sylvatic transmission while also preserving endangered susceptible species. The hypothesis of establishing an uncontrolled transmission of this attenuated virus in nature was raised. We assessed vector competence of four sylvatic mosquito species, Haemagogus leucocelaenus, Haemagogus janthinomys/capricornii, Sabethes albiprivus, and Sabethes identicus, as well as the urban vector Aedes aegypti for YF 17DD attenuated vaccine virus when fed directly on eleven viremic lion tamarins or artificially challenged with the same virus. No infection was detected in 689 mosquitoes engorged on viremic lion tamarins whose viremia ranged from 1.05 × 103 to 6.61 × 103 FFU/mL, nor in those artificially taking ≤ 1 × 103 PFU/mL. Low viremia presented by YF 17DD-vaccinated New World NHPs combined with the low capacity and null dissemination ability in sylvatic and domestic mosquitoes of this attenuated virus suggest no risk of its transmission in nature. Thus, vaccination of captive and free-living NHPs against YFV is a safe public health strategy.


  • Open Access

    Establishment 5 doses presentation of the triple viral vaccine without albumin to reduce loss during administration

    by Sérgio Assumpção, Marcos da Silva Freire, Elena Cristina Caride, Celso de Farias Crespo

  • Safety and immunogenicity of 17DD attenuated yellow fever vaccine in howler monkeys (Alouatta spp.)

    by André Tavares da Silva Fernandes, Silvia Bahadian Moreira, Luciane Pinto Gaspar, Marisol Simões, Ana Carolina dos Reis Albuquerque Cajaraville, Renata Carvalho Pereira, Mariana Pierre de Barros Gomes, José Henrique Rezende Linhares, Vanessa de Oliveira Santos, Renata Tourinho Santos, et al.

    Background: Alouatta spp. are highly susceptible to yellow fever (YF) infection and develop an often fatal disease. The threat posed by an outbreak started in 2016 leads us to investigate vaccination as a potential tool in preventing YF in non‐human primates (NHP).Methods: Susceptible howler monkeys were immunized with three different concentrations of the human Brazilian commercial YF17DD vaccine. Post‐vaccination viremia/RNAemia, immunogenicity, and safety were characterized.Results: The vaccine did not produce YF clinical manifestations in any of the NHPs. After immunization, all animals seroconverted demonstrating the ability of the YF vaccine to induce humoral response in Alouatta species.Conclusions: The present work has demonstrated the safe and immunogenic profile of the existing YF 17DD vaccine in howler monkeys. This knowledge may support further studies with other susceptible monkey species and provide a possible solution for controlling epizootics and preventing the devastation of endangered species.


  • Molecular Pharming for low and middle income countries

    by Sheeba Murad, Sebastian Fuller, Jonathan Menary, Cathy Moore, Elizabeth Pinneh, Tim Szeto, Inga Hitzeroth, Marcos Freire, Suthira Taychakhoonavudh, Waranyoo Phoolcharoen, et al.


  • Open Access

    Vaccines for neglected and emerging diseases in Brazil by 2030: the “valley of death” and opportunities for RD&I in Vaccinology 4.0

    by Akira Homma, Marcos da Silva Freire, Cristina Possas

    We examine the implications of the very low competitiveness of the Brazilian vaccine RD&I system, which precludes the development of all the important vaccines required by the National Immunization Program (NIP), severely impacting the healthcare of the population. In a country dramatically affected by COVID-19 pandemic and by an exponential increase in emerging and neglected diseases, particularly the poor, these RD&I constraints for vaccines become crucial governance issues. Such constraints are aggravated by a global scenario of limited commercial interest from multinational companies in vaccines for neglected and emerging diseases, which are falling into a “valley of death,” with only two vaccines produced in a pipeline of 240 vaccines. We stress that these constraints in the global pipeline are a window of opportunity for vaccine manufacturers in Brazil and other developing countries in the current paradigm transition towards Vaccinology 4.0. We conclude with recommendations for a new governance strategy supporting Brazilian public vaccine manufacturers in international collaborations for a sustainable national vaccine development and production plan by 2030.


  • Open Access

    A evolução regulatória e os desafios na perspectiva dos laboratórios públicos produtores de vacinas no Brasil

    by Monique Collaço de Moraes Stávale, Maria da Luz Fernandes Leal, Marcos da Silva Freire

    A regulamentação para produtos biológicos vem evoluindo rapidamente ao longo dos últimos anos, seja motivada por questões de qualidade com impacto na vida das pessoas, seja pelo advento de novas tecnologias. As mudanças nas regulamentações que ditam como um produto deve ser registrado, produzido e monitorado são constantes. A responsabilidade de reguladores e fabricantes na garantia da qualidade, segurança e eficácia das vacinas torna-se ainda mais crítica, uma vez que essas substâncias são utilizadas, em sua maioria, em crianças e em pacientes saudáveis. Diante desse cenário, fabricantes precisam criar estratégias para manter seus produtos e instalações adequadas e um sistema da qualidade atualizado e operante. Por outro lado, as agências reguladoras têm o papel de garantir que os produtos que estão em uso atendam aos critérios estabelecidos, sem comprometer o fornecimento de medicamentos para a população.